DIASORIN LAUNCHES THE NEW LIAISON SHBG TEST FOR THE DIAGNOSIS OF ANDROGEN-RELATED DISORDERS

May 23, 2017 - Saluggia (VC) - DiaSorin (FTSE Italy Mid Cap: DIA) is pleased to announce the launch of the new LIAISON test for the measurement of SHBG (Sex Hormone-Binding Globulin) in human serum and plasma, available worldwide with the exception of the U.S.

SHBG, which is produced in the liver, is involved in transport of sex steroids, such as dihydrotestosterone, testosterone and estradiol, in the blood stream.

The combined measurement of SHBG and testosterone levels helps determining causes of infertility, decreased libido and erectile dysfunction in men, and diagnosing polycystic ovarian syndrome (PCOS) in women.

The ratio of total testosterone level divided by SHBG level - called FAI (free androgen index) - is particularly useful during the diagnostic phase, and is widely used as it can easily measure androgen levels in comparison with more complex alternative methods.

According to the Global Diagnostic Market Statistics, the European infertility market is estimated at 130 million euros with SHBG accounting for about 4%, equal to a volume exceeding 2.7 million tests per year.

Francesco Colotta, Chief Medical Officer of DiaSorin, commented: "The LIAISON® SHBG test enriches our extensive number of products available in the endocrinology clinical area. This test is an important diagnostic tool for FAI calculation when combined with our testosterone test, which is already available on the market.

The growing presence of our products in the fertility segment confirms DiaSorin's commitment to increasing the number of effective diagnostic tools in this clinical area".

About DiaSorin

Headquartered in Italy and listed in the FTSE Italia Mid Cap Index, DiaSorin is a global leader in the In Vitro Diagnostics (IVD) field. For over 40 years the Company has been developing, producing and marketing reagent kits for IVD worldwide. Through constant investments in research and development, and using its own distinctive expertise in the field of immunodiagnostics to deliver a high level of innovation, DiaSorin offers today the broadest range of specialty tests available in the immunodiagnostics market and new tests in the molecular diagnostics markets, which identify DiaSorin Group as the IVD “diagnostics specialist”.

For additional information, please contact:

Riccardo Fava
Investor Relations & Corporate Communication Senior Director
Tel: +39.0161.487988
riccardo.fava@diasorin.it

Ines Di Terlizzi
Investor Relator
Tel: +39.0161.487567
ines.diterlizzi@diasorin.it